Wall Street analysts expect that Magenta Therapeutics Inc (NASDAQ:MGTA) will post earnings per share of ($0.55) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Magenta Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.54) and the lowest estimate coming in at ($0.55). The company is scheduled to issue its next earnings report on Thursday, February 14th.

According to Zacks, analysts expect that Magenta Therapeutics will report full year earnings of ($3.19) per share for the current financial year, with EPS estimates ranging from ($3.23) to ($3.15). For the next financial year, analysts anticipate that the company will post earnings of ($2.05) per share, with EPS estimates ranging from ($2.67) to ($1.12). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Magenta Therapeutics.

Magenta Therapeutics (NASDAQ:MGTA) last released its quarterly earnings results on Thursday, November 8th. The company reported ($0.49) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.67) by $0.18.

MGTA has been the subject of several analyst reports. Zacks Investment Research raised shares of Magenta Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 10th. ValuEngine lowered shares of Magenta Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, January 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. Magenta Therapeutics presently has an average rating of “Buy” and an average target price of $19.33.

NASDAQ MGTA opened at $5.84 on Friday. Magenta Therapeutics has a 52 week low of $5.31 and a 52 week high of $16.33.

A number of institutional investors have recently added to or reduced their stakes in the stock. Point72 Hong Kong Ltd purchased a new stake in Magenta Therapeutics in the 2nd quarter worth approximately $109,000. Point72 Asset Management L.P. purchased a new stake in Magenta Therapeutics in the 2nd quarter worth approximately $109,000. Northern Trust Corp purchased a new stake in Magenta Therapeutics in the 2nd quarter worth approximately $179,000. Platinum Investment Management Ltd. increased its holdings in Magenta Therapeutics by 47.4% in the 3rd quarter. Platinum Investment Management Ltd. now owns 73,700 shares of the company’s stock worth $885,000 after acquiring an additional 23,700 shares in the last quarter. Finally, Bollard Group LLC purchased a new stake in Magenta Therapeutics in the 3rd quarter worth approximately $360,000. 30.79% of the stock is owned by institutional investors.

About Magenta Therapeutics

Magenta Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases.

Read More: How Do You Calculate Return on Investment (ROI)?

Get a free copy of the Zacks research report on Magenta Therapeutics (MGTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.